Pharma BD Deal Intelligence
Genzyme sold Verigen's MACI asset for a $6.5M fire-sale price in 2014 — two years before it became a $150M+/year blockbuster for the buyer, Vericel.
Full analysis, sources & comparables →Genzyme has acquired Verigen for $10 million in initial payments, and potential additional payments of up to $40 million over the next six years based upon the…
MACI was designed to overcome the surgical complexity and invasiveness associated with first-generation ACI, replacing the periosteal cover with a porcine…
MACI received FDA approval in December 2016 for the repair of symptomatic, full-thickness cartilage defects of the knee in adult patients, becoming the first…
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
Genzyme acquires German cell-therapy/cartilage-repair specialist Verigen AG, expanding orthopedic/biosurgery portfolio. Terms undisclosed.
Genzyme sold Verigen's MACI asset for a $6.5M fire-sale price in 2014 — two years before it became a $150M+/year blockbuster for the buyer, Vericel.
Assessment window: 15yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Genzyme Corporation / Verigen AG (this deal) | 2005 | $50M | 29 |
| Genzyme Corporation / SangStat Medical Corporation | 2003 | $600M | 78 |
| Genzyme Corporation / ILEX Oncology Inc. | 2004 | $1.0B | 66 |
| Genzyme Corporation / Biomatrix Inc. | 2000 | $700M | 65 |
| Genzyme Corporation / Bone Care International, Inc. | 2005 | $600M | 61 |
| Genzyme Corporation / Novazyme Pharmaceuticals Inc. | 2001 | $138M | 54 |
| AstraZeneca PLC / KuDOS Pharmaceuticals Limited | 2005 | $210M | 98 |
← Browse all deals · How we score deals
More: 2005 deals · Genzyme Corporation deals